Cargando…

Future perspectives of uveal melanoma blood based biomarkers

Uveal melanoma (UM) is the most common primary intraocular malignancy affecting adults. Despite successful local treatment of the primary tumour, metastatic disease develops in up to 50% of patients. Metastatic UM carries a particularly poor prognosis, with no effective therapeutic option available...

Descripción completa

Detalles Bibliográficos
Autores principales: Beasley, Aaron B., Chen, Fred K., Isaacs, Timothy W., Gray, Elin S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130512/
https://www.ncbi.nlm.nih.gov/pubmed/35190695
http://dx.doi.org/10.1038/s41416-022-01723-8
_version_ 1784712986706837504
author Beasley, Aaron B.
Chen, Fred K.
Isaacs, Timothy W.
Gray, Elin S.
author_facet Beasley, Aaron B.
Chen, Fred K.
Isaacs, Timothy W.
Gray, Elin S.
author_sort Beasley, Aaron B.
collection PubMed
description Uveal melanoma (UM) is the most common primary intraocular malignancy affecting adults. Despite successful local treatment of the primary tumour, metastatic disease develops in up to 50% of patients. Metastatic UM carries a particularly poor prognosis, with no effective therapeutic option available to date. Genetic studies of UM have demonstrated that cytogenetic features, including gene expression, somatic copy number alterations and specific gene mutations can allow more accurate assessment of metastatic risk. Pre-emptive therapies to avert metastasis are being tested in clinical trials in patients with high-risk UM. However, current prognostic methods require an intraocular tumour biopsy, which is a highly invasive procedure carrying a risk of vision-threatening complications and is limited by sampling variability. Recently, a new diagnostic concept known as “liquid biopsy” has emerged, heralding a substantial potential for minimally invasive genetic characterisation of tumours. Here, we examine the current evidence supporting the potential of blood circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), microRNA (miRNA) and exosomes as biomarkers for UM. In particular, we discuss the potential of these biomarkers to aid clinical decision making throughout the management of UM patients.
format Online
Article
Text
id pubmed-9130512
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-91305122022-05-26 Future perspectives of uveal melanoma blood based biomarkers Beasley, Aaron B. Chen, Fred K. Isaacs, Timothy W. Gray, Elin S. Br J Cancer Review Article Uveal melanoma (UM) is the most common primary intraocular malignancy affecting adults. Despite successful local treatment of the primary tumour, metastatic disease develops in up to 50% of patients. Metastatic UM carries a particularly poor prognosis, with no effective therapeutic option available to date. Genetic studies of UM have demonstrated that cytogenetic features, including gene expression, somatic copy number alterations and specific gene mutations can allow more accurate assessment of metastatic risk. Pre-emptive therapies to avert metastasis are being tested in clinical trials in patients with high-risk UM. However, current prognostic methods require an intraocular tumour biopsy, which is a highly invasive procedure carrying a risk of vision-threatening complications and is limited by sampling variability. Recently, a new diagnostic concept known as “liquid biopsy” has emerged, heralding a substantial potential for minimally invasive genetic characterisation of tumours. Here, we examine the current evidence supporting the potential of blood circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), microRNA (miRNA) and exosomes as biomarkers for UM. In particular, we discuss the potential of these biomarkers to aid clinical decision making throughout the management of UM patients. Nature Publishing Group UK 2022-02-21 2022-06-01 /pmc/articles/PMC9130512/ /pubmed/35190695 http://dx.doi.org/10.1038/s41416-022-01723-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Review Article
Beasley, Aaron B.
Chen, Fred K.
Isaacs, Timothy W.
Gray, Elin S.
Future perspectives of uveal melanoma blood based biomarkers
title Future perspectives of uveal melanoma blood based biomarkers
title_full Future perspectives of uveal melanoma blood based biomarkers
title_fullStr Future perspectives of uveal melanoma blood based biomarkers
title_full_unstemmed Future perspectives of uveal melanoma blood based biomarkers
title_short Future perspectives of uveal melanoma blood based biomarkers
title_sort future perspectives of uveal melanoma blood based biomarkers
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130512/
https://www.ncbi.nlm.nih.gov/pubmed/35190695
http://dx.doi.org/10.1038/s41416-022-01723-8
work_keys_str_mv AT beasleyaaronb futureperspectivesofuvealmelanomabloodbasedbiomarkers
AT chenfredk futureperspectivesofuvealmelanomabloodbasedbiomarkers
AT isaacstimothyw futureperspectivesofuvealmelanomabloodbasedbiomarkers
AT grayelins futureperspectivesofuvealmelanomabloodbasedbiomarkers